基于亚结构侵犯风险的初治鼻咽癌临床靶区个体化勾画:一项大样本前瞻性真实世界研究
这项前瞻性真实世界研究先在354例初诊鼻咽癌患者中分析局部侵犯模式,将鼻咽周围结构按侵犯风险分为1至4级亚结构,再据此制定个体化临床靶区勾画方案并纳入无远处转移的初治鼻咽癌患者,所有患者接受调强放疗,CTV1与CTV2处方剂量分别为60 Gy与54 Gy、30~33次。结果显示全研究队列(N=1004)5年局部无复发生存率为93.2%、总生存率为91.5%,3级晚期毒性总发生率为1.5%。作者认为该个体化勾画方法可获得良好的局部肿瘤控制与长期生存,晚期毒性可接受。
要点
- 全研究队列N=1004,中位随访66.6个月,5年局部无复发生存率93.2%、总生存率91.5%。
- 训练集与验证集5年局部无复发生存率分别为93.0%与93.2%,5年总生存率分别为88.5%与93.4%。
- 69例局部复发中67例(97.1%)位于高剂量区,3级晚期毒性总发生率为1.5%。
核心结论
- 作者认为,基于距离加亚结构的个体化临床靶区勾画方法可获得良好的局部肿瘤控制与长期生存结局,晚期毒性可接受。
研究设计与样本
- 前瞻性真实世界研究;先对354例初诊鼻咽癌患者的局部侵犯模式进行初步研究,将鼻咽周围结构按侵犯风险分为1至4级亚结构,再纳入无远处转移的初诊鼻咽癌患者验证个体化临床靶区勾画方案。
- 2008年1月至2012年12月入组356例(训练集),2013年1月至2019年9月入组648例(验证集);所有患者接受调强放疗,CTV1与CTV2处方剂量分别为60 Gy与54 Gy、30~33次。
- 主要终点为局部无复发生存率,次要终点包括区域控制与生存,采用Kaplan-Meier法估计,并分析局部失败模式。
主要发现
- 训练集中位随访104.6个月(四分位间距73.1-126.9),验证集中位随访51.4个月(39.5-78.5);训练集31例(8.7%)、验证集38例(5.9%)出现局部复发,5年局部无复发生存率分别为93.0%与93.2%。
- 训练集63例(17.7%)、验证集39例(6%)死亡,5年总生存率分别为88.5%与93.4%。
- 全研究队列(N=1004)中位随访66.6个月(41.5-98.0),5年局部无复发生存率与总生存率分别为93.2%与91.5%。
- 3级晚期毒性包括口干、皮下纤维化、听力损伤、张口受限、视力损伤与皮肤萎缩,总发生率为1.5%。
- 69例局部复发中67例(97.1%)位于高剂量区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The delineation of clinical target volume (CTV) for primary nasopharyngeal carcinoma (NPC) is currently controversial and the international guideline still recommend a uniform border for CTV regardless of the tumor extent. We conducted this prospective, real-world study to evaluate the clinical outcomes of our individualized CTV delineation method based on distance plus substructures. MATERIALS AND METHODS: We preliminarily investigated the local extension patterns of NPC on 354 newly diagnosed patients and defined the structures surrounding the nasopharynx as Level-1 to Level-4 substructures stratified by the risk of invasion. We then enrolled patients with newly diagnosed NPC without distant metastasis to investigate our individualized CTV delineation protocol. All patients received intensity modulated radiotherapy. CTV1 and CTV2 were prescribed doses of 60 Gy and 54 Gy in 30 ∼ 33 fractions. The primary endpoint was local recurrence-free survival (LRFS); secondary endpoints included regional control and survival, estimated using the Kaplan-Meier method. The local failure patterns were also analyzed. RESULTS: From January 2008 to December 2012 and from January 2013 to September 2019, 356 and 648 patients were enrolled, named as training set and validation set, respectively. With a median follow-up of 104.6 (interquartile, 73.1-126.9) and 51.4 (39.5-78.5) months, 31 (8.7 %) and 38 (5.9 %) patients in training and validation sets experienced local recurrence, and the 5-year LRFS was 93.0 % and 93.2 %, respectively; 63 (17.7 %) and 39 (6 %) patients died in training and validation sets, and the 5-year overall survival (OS) was 88.5 % and 93.4 %, respectively. For the whole study cohort (N = 1004) with a median follow-up of 66.6 (41.5-98.0) months, the 5-year LRFS and OS was 93.2 % and 91.5 %. The grade 3 late toxicities included xerostomia, subcutaneous fibrosis, hearing impairment, trismus, visuality impairment and skin atrophy, with a total incidence of 1.5 %. Sixty-seven of 69 (97.1 %) local recurrence was in high-dose area. CONCLUSION: Our individualized CTV delineation method can achieve favorable local tumor control and long-term survival outcomes with acceptable late toxicities.
引用
- Wang X, Huang N, Yip PL, et al. The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-world study with a large population. Radiother Oncol. 2024. PMID: 38367938. doi:10.1016/j.radonc.2024.110154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。